Acute Porphyria Drug Database

A10BB12 - Glimepiride
Propably not porphyrinogenic
PNP

Rationale
Glimepiride is metabolized by CYP2C9. There are no clinical studies indicating that glipizide is an inhibitor or inducer of CYP enzymes.
Chemical description
Sulfonylourea.
Therapeutic characteristics
Glimepirid is indicated for the treatment of diabetes type 2. Very rare side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are nausea, vomiting, diarrhoea and abdominal pain. A rare side effect is hypoglycaemia, which also may be potentially porphyrinogenic.
Metabolism and pharmacokinetics
Glimepirid is metabolized mainly by CYP2C9 (Holstein 2012) and the elimination half-life is 5-8 hours. There are no clinical studies indicating that glipizide is an inhibitor or inducer of CYP enzymes.
IPNet drug reports
Uneventful use reported in 5 patients with acute porphyria.

References

  1. Scientific articles
  2. Holstein A, Beil W, Kovacs P. CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects. Expert Opin Drug Metab Toxicol. 2012 Dec;8(12):1549-63. PMID 23153186. #1004
  3. Summary of Product Characteristics
  4. Norwegian medicines agency. Summary of Product Characteristics (SPC). (glimepirid). #1113

Similar drugs
Explore alternative drugs in similar therapeutic classes A10B / A10BB or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙